ANTIPLATELET DRUGS MARKET ANALYSIS

Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI2190
Pages :185
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Antiplatelet Drugs Market: Key Developments

In May 2022, Shanghai MicroPort Medical (Group) Co., Ltd. a subsidiary of MicroPort Scientific Corporation, announced that the TARGET Dual antiplatelet therapy study, one of the pivotal post-market clinical studies of the Firehawk Rapamycin Target Eluting Coronary Stent System (Firehawk) completed subject enrollment. The TARGET Dual antiplatelet therapy study is a prospective, multicenter, non-inferiority, randomized, and controlled clinical trial. This study further, in May 21 2022, demonstrated that Firehawk could achieve rapid healing with equal or better safety and efficacy at the world’s lowest dosage — one-third of that of competing products, even when used in high-risk, complex patients.